Fredrik Wermeling, PhD
(Photo Karin Nordin/SSF, from the ceremony for the Ingvar Carlsson Award 2013)
Education and Positions:
- 2002-2006 / Master of Science in Biomedicine, Karolinska Institutet, including one semester 2004 at the Leids Universitair Medisch Centrum (LUMC), Leiden, the Netherlands.
- 2005-2006 / Stockholm Research School of Molecular Life Sciences, Karolinska Institutet, including three 10 week projects; in the group of Dr. Karl Tryggvason and Dr. Annika Scheynius, Karolinska Institutet, as well as at AstraZeneca R&D Södertälje. 15 positions/year, obtained in national competition. Financed by the Foundation for Strategic Research (SSF).
- 2006-2010 / PhD Student, Clinical Allergy Research Unit, Karolinska Institutet. Thesis: “Innate mechanisms regulating peripheral B cell tolerance” (link). Main supervisor: Dr. Mikael C. Karlsson, co-supervisor: Dr. Ola Winqvist. Thesis defence May 12th 2010 with opponent Dr. Keith B. Elkon, University of Washington, Seattle, USA. / Mainly working on how excessive cell death can trigger autoreactive activation of B cells (suggested to be involved in the pathogenesis of SLE). Focus on macrophage interactions (Wermeling et al, JEM, 2007) and iNKT cell interactions (Wermeling et al, JEM, 2010).
- 2010-2013 / Postdoctoral fellow with Dr. Jeffrey V. Ravetch, Rockefeller University, New York. Funded by a generous fellowship from the Wenner-Gren foundations. / Studies of IgG antibodies and Fc-gamma Receptors in models for inflammatory disease. Main focus on anti-inflammatory properties of STAT6 signaling (Anthony et al, Nature, 2011 and Wermeling et al, PNAS, 2013).
- 2013- / Team leader, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet.
- 2015-/ Assistant professor, Rheumatology Unit, Karolinska Institutet. Funded by the Karolinska Institutet faculty funded career position program, acceptance rate for grant 6.8%.